Skip to main content
. 2021 Jun 8;4:699. doi: 10.1038/s42003-021-02191-1

Fig. 4. Immune PD of CA-170 in CT26 colon carcinoma model.

Fig. 4

CT26 tumor bearing mice were dosed with CA-170 at 10 mg/kg daily along with a vehicle control and a PD-1 antibody control (J43 Clone, 100 µg/animal) (n = 5). After 5 days of dosing the tumor infiltrating lymphocytes were labeled with Ki67 as a measure of proliferation and OX-40 as an indicator of T-cell activation. a–b Increase in the proliferating and activated CD8 + T cells. c–d Increase in the proliferating and activated CD4 + T cells. e–f Increase in granzyme B and g–h IFN-γ secreting CD8 + T cells in blood and tumor of MC38-tumor bearing mice dosed daily at 3 mg/kg for 7 days. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 as calculated by one-way ANOVA (Dunnett’s multiple comparisons test).